Publications by authors named "P Herlemont"

Importance: Cancer is a leading cause of death among children worldwide. Treatments used for medically assisted reproduction (MAR) are suspected risk factors because of their potential for epigenetic disturbance and associated congenital malformations.

Objective: To assess the risk of cancer, overall and by cancer type, among children born after MAR compared with children conceived naturally.

View Article and Find Full Text PDF
Article Synopsis
  • * Among over 7.5 million pregnancies, antibacterial use dropped from 41.5% to 36.1%, while the use of antiviral drugs and the influenza vaccine significantly increased over the same period.
  • * Despite a small rise in exposure to potentially harmful anti-infective agents, the prescriptions generally adhered to safety recommendations, highlighting a need for better influenza vaccination practices during pregnancy.
View Article and Find Full Text PDF

Objective: To investigate whether the initiation of treatment with an interleukin-17 inhibitor (IL-17i) in real life is associated with a higher risk of inflammatory bowel disease (IBD) in patients who had both psoriasis (PsO) and psoriatic arthritis (PsA)/ankylosing spondylitis (AS).

Methods: This nationwide cohort study was conducted using the French National Health Data System database. All adult patients with PsO and PsA/AS who were identified as having newly initiated treatment with an IL-17i during 2016-2019 were included.

View Article and Find Full Text PDF

After initially hypothesizing a positive relationship between use of renin-angiotensin-aldosterone system inhibitors and risk of coronavirus disease 2019 (COVID-19), more recent evidence suggests negative associations. We examined whether COVID-19 risk differs according to antihypertensive drug class in patients treated by ACE (angiotensin-converting enzyme) inhibitors and angiotensin receptor blockers (ARBs) compared with calcium channel blockers (CCBs). Three exclusive cohorts of prevalent ACE inhibitors, ARB and CCB users, aged 18 to 80 years, from the French National Health Insurance databases were followed from February 15, 2020 to June 7, 2020.

View Article and Find Full Text PDF